Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

These novel Selenium-based compounds demonstrated remarkable improvement when treating ALS

Staff Writer
Staff Writer 2 years ago
Updated 2021/10/23 at 2:25 PM
Share
SHARE

Since the discovery of the first amyotrophic lateral sclerosis (ALS) gene in the early 1990s, research has only yielded the approval of two drug treatments for the neurodegenerative disease.

But in new research released in the journal EBioMedicine, a coalition of researchers at the University of Liverpool and Nagoya University, uncovered new drug candidates with promising therapeutic potential for the treatment of ALS, commonly referred to as motor neurone disease.

ALS, by definition, is a progressive neurological condition resulting in the death of neurons involved in the controlling of voluntary muscles. There is no cure in existence for ALS, but riluzole and edaravone have been used to combat the disease.

In their new study, the research team developed ebselen-based compounds with stabilized improvements in superoxide dismutase (SOD1), a protein implicated in some instances of ALS. The compounds were also associated with in vitro therapeutic effects, demonstrating substantially better potency compared to the treatment edaravone.

“We have utilised the ebselen template to develop novel compounds that redeem stability of mutant SOD1 dimer and prevent aggregation,” the research team explained in their research paper.

“Binding modes of compounds have been visualised by crystallography. In vitro neuroprotection and toxicity of lead compounds have been performed in mouse neuronal cells and disease onset delay of ebselen has been demonstrated in transgenic ALS mice model,” they also stated.

“We have developed a number of ebselen-based compounds with improvements in A4V SOD1 stabilisation and in vitro therapeutic effects with significantly better potency than edaravone.”

According to researchers, the findings point to a potential new class of drug candidates in the near future for the treatment of ALS.

“The potential of this class of compounds may offer an alternative therapeutic agent for ALS treatment,” researchers concluded in their paper. “The ability of these compounds to target cysteine 111 in SOD may have wider therapeutic applications targeting cysteines of enzymes involved in pathogenic and viral diseases including main protease of SARS-Cov-2.”

Photo: Andrea Danti

You Might Also Like

MIT study shows how microglia can contribute to Alzheimer’s disease

New paper refutes theory that the human brain shrank 3,000 years ago

New study finds that people with autism are more skilled at reading emotions in cartoons

New report explores the link between dementia and air pollution

How herpes simplex virus may help trigger the onset of Alzheimer’s disease

TAGGED: ebselen, edaravone, ALS, amyotrophic lateral sclerosis
Staff Writer September 1, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Physical exercise reduces stress by heightening levels of brainstem protein galanin
Next Article How a region of the cerebellum plays a crucial role in split-second decisions

Recommended

Clinical

MIT study shows how microglia can contribute to Alzheimer’s disease

1 Min Read
Clinical

New paper refutes theory that the human brain shrank 3,000 years ago

1 Min Read
Clinical

New study finds that people with autism are more skilled at reading emotions in cartoons

1 Min Read
Clinical

New report explores the link between dementia and air pollution

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?